Arcus Biosciences (RCUS) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed Zai Lab (ZLAB) over the past year, gaining 58.3% versus a loss of 26.4%. Over five years, RCUS leads with a -30.7% price change compared with -75.7% for ZLAB. Arcus Biosciences is the larger company by market cap ($3.07 billion vs $2.81 billion), about 1.1 times the size, while Zai Lab is growing revenue faster (+15.3% vs -4.3%).
Zai Lab converts more of its revenue into profit, with a net margin of -38.1% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCUS | ZLAB |
|---|---|---|
| Share price | $24.41 | $24.99 |
| Market cap | $3.07B | $2.81B |
| 1-day change | +2.43% | +0.73% |
| YTD return | 0.00% | +40.65% |
| 1-year return | +58.34% | -26.36% |
| 5-year return | -30.71% | -75.68% |
| EPS (TTM) | $-3.91 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $247.00M | $460.16M |
| Revenue growth (YoY) | -4.26% | +15.33% |
| Net income (latest FY) | $-353.00M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | -156.28% | -49.86% |
| Net margin | -142.91% | -38.15% |
| 52-week high | $31.74 | $32.76 |
| 52-week low | $14.26 | $15.96 |
| Distance from 52-week high | -23.08% | -23.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.50% | +32.61% |
| Average volume | 1.34M | 945.51K |
| Shares outstanding | 125.77M | 112.27M |
| Employees | 601 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed ZLAB by 84.7 percentage points over the past year.
- Zai Lab is more profitable, keeping -38.1 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
- Zai Lab grew revenue faster in its latest fiscal year (+15.33% vs -4.26%).
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
RCUS vs ZLAB FAQ
Which is bigger, Arcus Biosciences or Zai Lab?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.07B compared with $2.81B for Zai Lab (ZLAB).
Which stock has performed better over the past year, RCUS or ZLAB?
RCUS returned +58.34% over the past 12 months, compared with -26.36% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Arcus Biosciences and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.